IP Verse

Compound For Use In The Treatment Of Ocular Disorders

Patent No. EP3811943 (titled "Compound For Use In The Treatment Of Ocular Disorders") was filed by Aerie Pharmaceuticals on Mar 14, 2014. The application was issued on Feb 22, 2023.

Patent Summary

Treating an ocular disorder in a subject in need of treatment. The treatment includes administering to the subject an isoquinoline compound, a prostaglandin or a prostaglandin analog, a prostaglandin selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF1 isopropyl ester, PGF2, isopropyl ester PGF3 isopropyl ester, and fluprostenol isopropyl ester.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKNov 22, 2023RUSSELL
ISARPATENT PATENT UND RECHTSANWALTE BARTH HASSA PECKMANN UND PARTNER MBBNov 22, 2023ISARPATENT
TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBNov 22, 2023TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3811943

AERIE PHARMACEUTICALS
Application Number
EP20207657A
Filing Date
Mar 14, 2014
Status
Granted And Under Opposition
Jan 20, 2023
Publication Date
Feb 22, 2023
External Links
Slate, Register , Google Patents